New Zealand markets closed

Charles River Laboratories International, Inc. (CRL)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
198.15-10.48 (-5.02%)
At close: 04:00PM EDT
198.15 0.00 (0.00%)
After hours: 04:27PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000

IndustryDiagnostics & Research
Full-time employees20,000

Key executives

NameTitlePayExercisedYear born
Mr. James C. Foster J.D.Chairman, CEO & Pres2.51M6.13M1951
Ms. Flavia H. PeaseCorp. Exec. VP & CFO772.4kN/A1973
Ms. Birgit GirshickCorp. Exec. VP & COO1.15MN/A1970
Mr. Joseph W. LaPlumeCorp. Exec. VP of Corp. Devel. & Strategy871.35k887.84k1974
Mr. William D. BarboChief Commercial Officer & Corp. Exec. VP928.55k354.38k1961
Mr. Michael Gunnar KnellCorp. Sr. VP & Chief Accounting OfficerN/AN/A1977
Prof. Julie Frearson Ph.D.Corp. Sr. VP & Chief Scientific OfficerN/AN/AN/A
Mr. Mark MintzCorp. Sr. VP & Chief Information OfficerN/AN/AN/A
Todd SpencerCorp. VP of Investor RelationsN/AN/AN/A
Mr. Matthew L. DanielCorp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Corporate governance

Charles River Laboratories International, Inc.’s ISS governance QualityScore as of 1 September 2023 is 7. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.